Diadema Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Diadema Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-190,928	Closed	-$1.49M	–	156
2025 Q4	$1.49M	Buy	+190,928	New	+$1.38M	0.26%	79

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Diadema Partners's BCRX Position: Q1 2026 in Review

Diadema Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 190,928 shares — an estimated $1.49M sold.

Diadema Partners first reported a position in BCRX in Q4 2025 and held it in 1 quarter. The position peaked at $1.49M in Q4 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Diadema Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 190,928 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.49M.
Diadema Partners first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Diadema Partners's BioCryst Pharmaceuticals position peaked at $1.49M in Q4 2025.
302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.